Esperion Therapeutics Files 8-K on Financials
Ticker: ESPR · Form: 8-K · Filed: Aug 5, 2025 · CIK: 1434868
| Field | Detail |
|---|---|
| Company | Esperion Therapeutics, Inc. (ESPR) |
| Form Type | 8-K |
| Filed Date | Aug 5, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, exhibits
TL;DR
Esperion Therapeutics dropped an 8-K on 8/5/25 covering financials. Check it out.
AI Summary
Esperion Therapeutics, Inc. filed an 8-K on August 5, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Ann Arbor, MI.
Why It Matters
This 8-K filing provides crucial updates on Esperion Therapeutics' financial performance and condition, which is essential for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Esperion Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- Esperion Therapeutics, Inc. (company) — Registrant
- August 5, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Ann Arbor, MI (location) — Principal Executive Offices
- HDL THERAPEUTICS INC (company) — Former Company Name
FAQ
What specific financial information is being reported in this 8-K?
The 8-K filing indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K filing submitted?
The filing was submitted on August 5, 2025.
Where are Esperion Therapeutics' principal executive offices located?
The principal executive offices are located at 3891 Ranchero Drive, Suite 150, Ann Arbor, MI 48108.
What is Esperion Therapeutics' state of incorporation?
Esperion Therapeutics, Inc. is incorporated in Delaware.
Has the company undergone a name change previously?
Yes, the company was formerly known as HDL THERAPEUTICS INC, with a date of name change on May 13, 2008.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on August 5, 2025 regarding Esperion Therapeutics, Inc. (ESPR).